James Hambro & Partners
TMO icon

James Hambro & Partners’s Thermo Fisher Scientific TMO Stock Holding History

James Hambro & Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$156M Buy
231,390
+1,919
+0.8% +$1.14M 5.45% 9
2026
Q2 		$115M Sell
229,471
-11,238
-5% -$5.39M 4.16% 10
2026
Q1 		$118M Sell
240,709
-630
-0.3% -$342K 4.64% 9
2025
Q4 		$140M Sell
241,339
-8,393
-3% -$4.75M 5% 7
2025
Q3 		$121M Sell
249,732
-7,595
-3% -$3.54M 4.3% 10
2025
Q2 		$104M Buy
257,327
+22,904
+10% +$9.6M 4.13% 14
2025
Q1 		$117M Buy
234,423
+12,219
+5% +$6.62M 4.87% 10
2024
Q4 		$116M Buy
222,204
+12,751
+6% +$7.01M 4.56% 11
2024
Q3 		$130M Buy
209,453
+11,276
+6% +$6.67M 5.4% 8
2024
Q2 		$109M Buy
198,177
+5,213
+3% +$2.99M 5.09% 11
2024
Q1 		$112M Buy
192,964
+5,071
+3% +$2.85M 5.25% 7
2023
Q4 		$100M Buy
187,893
+16,594
+10% +$8.03M 5.31% 8
2023
Q3 		$86.7M Buy
171,299
+13,937
+9% +$7.43M 5.62% 7
2023
Q2 		$82.1M Buy
157,362
+8,193
+5% +$4.42M 5.41% 6
2023
Q1 		$86M Buy
149,169
+2,896
+2% +$1.63M 6.28% 5
2022
Q4 		$80.6M Buy
146,273
+559
+0.4% +$296K 6.15% 4
2022
Q3 		$74M Sell
145,714
-4,263
-3% -$2.39M 6.45% 4
2022
Q2 		$81.6M Sell
149,977
-69
-0% -$38K 6.8% 5
2022
Q1 		$88.7M Buy
150,046
+181
+0.1% +$104K 6.3% 4
2021
Q4 		$100M Buy
149,865
+464
+0.3% +$290K 6.79% 4
2021
Q3 		$85.3M Buy
149,401
+7,866
+6% +$4.32M 6.37% 4
2021
Q2 		$71.4M Buy
141,535
+10,286
+8% +$4.85M 5.66% 6
2021
Q1 		$59.9M Buy
131,249
+11,906
+10% +$5.68M 5.54% 7
2020
Q4 		$55.6M Buy
119,343
+9,352
+9% +$4.38M 6.23% 6
2020
Q3 		$48.5M Buy
109,991
+88,792
+419% +$36.7M 6.84% 6
2020
Q2 		$7.67M Buy
21,199
+19,199
+960% +$6.44M 1.19% 20
2020
Q1 		$567K Hold
2,000
– – 0.11% 33
2019
Q4 		$649K Hold
2,000
– – 0.11% 31
2019
Q3 		$583K Buy
+2,000
New +$573K 0.12% 30
2019
Q1 		$547K Hold
2,000
– – 0.16% 29
2018
Q4 		$447K Buy
+2,000
New +$469K 0.18% 32

Other funds holding TMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

James Hambro & Partners's TMO Position: Q3 2026 in Review

James Hambro & Partners increased its Thermo Fisher Scientific (TMO) stake by 0.84% in Q3 2026, buying an estimated $1.14M and bringing the position to 231,390 shares worth $156M. The position accounts for 5.45% of the portfolio, ranked #9.

James Hambro & Partners first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. 1,885 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • James Hambro & Partners held 231,390 shares of Thermo Fisher Scientific worth $156M as of Q3 2026.
  • James Hambro & Partners bought 1,919 Thermo Fisher Scientific shares in Q3 2026, an estimated $1.14M.
  • Thermo Fisher Scientific made up 5.45% of James Hambro & Partners's portfolio in Q3 2026, its #9 holding.
  • James Hambro & Partners first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
  • 1,885 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on James Hambro & Partners's 13F filing for Q3 2026, filed 19 Oct 2026.